RE: Boehringer Ingelheim Great find.
Looking at the studies below, does it leave in vivo studies with mice and PGX Y-BG as a carrier for nintedanib to be conducted. If these pre-clinical mouse studies are successful, it seems possible that Boehringer Ingelheim would be a potential partner with Ceapro to conduct phase 1 clinical studies.
The August NR expanding the work between Ceapro and McMaster makes all the sense now and the potential to get a pharma partner for phase 1 human trials could be on the horizon.
"We used nintedanib, a broad kinase inhibitor, approved for idiopathic pulmonary fibrosis (IPF) to dissect lung macrophage phenotypes during fibrosis-linked inflammation by combining in vivo and in vitro bulk and single cell RNA sequencing approaches. In the bleomycin model, nintedanib drove expression of IL-4/IL-13 associated genes important for tissue regeneration and repair at early and late time points in lung macrophages. These findings were replicated in vitro in mouse primary bone marrow derived macrophages exposed to IL-4/IL-13 and nintedanib. In addition, nintedanib promoted expression of IL-4/IL-13 pathway genes in human macrophages in vitro."